GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Cyclically Adjusted Price-to-FCF

Amryt Pharma (Amryt Pharma) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Amryt Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Amryt Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Cyclically Adjusted Price-to-FCF Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amryt Pharma's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amryt Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Cyclically Adjusted Price-to-FCF falls into.



Amryt Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Amryt Pharma's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec21 is calculated as:

For example, Amryt Pharma's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec21 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec21 (Change)*Current CPI (Dec21)
=0.283/114.7000*114.7000
=0.283

Current CPI (Dec21) = 114.7000.

Amryt Pharma Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201203 -0.021 95.400 -0.025
201303 -0.169 97.800 -0.198
201403 -0.212 99.300 -0.245
201503 -0.323 99.600 -0.372
201612 -1.183 102.200 -1.328
201712 -1.967 105.000 -2.149
201812 -1.713 107.100 -1.835
201912 -2.512 108.500 -2.656
202012 0.770 109.400 0.807
202112 0.283 114.700 0.283

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amryt Pharma  (NAS:AMYT) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Amryt Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).